InsiderSignal.AI

InsiderSignal.ai

BCAX - Bicara Therapeutics Inc.

Insider Sale by Raben David (Chief Medical Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Raben David, serving as Chief Medical Officer at Bicara Therapeutics Inc. (BCAX), sold 5,500 shares at $22.88 per share, for a total transaction value of $125,830.00. Following this transaction, Raben David now holds 55,286 shares of BCAX.

This sale represents a 9.00% decrease in Raben David's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 27, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 28, 2026, 1 day after the trade was made.

Bicara Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Raben David

Chief Medical Officer

David Raben, M.D. is the Chief Medical Officer at Bicara Therapeutics Inc. (BCAX), a board-certified radiation oncologist with over 25 years of experience in biopharma and academic translational oncology.[[1]](https://fintool.com/app/research/companies/BCAX/people/david-raben)[[6]](https://www.bicara.com/team/david-raben/) He joined the company as a consultant in May 2023 and was appointed CMO in July 2023.[[1]](https://fintool.com/app/research/companies/BCAX/people/david-raben) Dr. Raben previously served as VP of Late-Stage Product Development at Amgen (Nov 2021–May 2023), leading the FDA-approved tarlatamab program for small cell lung cancer (SCLC), and at Genentech (Sep 2019–Jun 2021) overseeing late-stage development in lung, skin, and head and neck cancer (HNC).[[1]](https://fintool.com/app/research/companies/BCAX/people/david-raben) Earlier, he was Professor of Radiation Oncology at the University of Colorado Health (1998–2019).[[1]](https://fintool.com/app/research/companies/BCAX/people/david-raben) His education includes a BA from Duke University (1985), an M.D. from Wake Forest University (1990), and residency at Johns Hopkins (1994).[[1]](https://fintool.com/app/research/companies/BCAX/people/david-raben) As of early 2026, he has engaged in insider trading activities, including selling shares under a Rule 10b5-1 plan adopted in February 2025 and receiving a 100,000-share option grant in February 2026.[[2]](https://www.investing.com/news/insider-trading-news/david-raben-bicara-therapeutics-cmo-sells-405k-in-bcax-stock-93CH-4282800)[[3]](https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-80a842ff4fb5.html)[[4]](https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-a0fdfb505973.html)

View full insider profile →

Trade Price

$22.88

Quantity

5,500

Total Value

$125,830.00

Shares Owned

55,286

Trade Date

Monday, April 27, 2026

4 days ago

SEC Filing Date

Tuesday, April 28, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning BCAX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6026754

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime